Antihyperglycemic Medications and Cardiovascular Risk Reduction

Cardiovascular disease (CVD) remains a leading cause of death in patients with type 2 diabetes (T2D). In addition to glycemic control, a major focus of diabetes treatment involves cardiovascular (CV) risk reduction. In 2008, the US Food and Drug Administration (FDA) instituted a new requirement that...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur Endocrinol
Main Authors: Anderson, Sarah L, Marrs, Joel C
Format: Artigo
Sprog:Inglês
Udgivet: Touch Medical Media 2017
Fag:
Cardiovascular Risk Reduction
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813471/
https://ncbi.nlm.nih.gov/pubmed/29632614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2017.13.02.86
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker